Trials in isolated systolic hypertension: An update

Current Cardiology Reports

Volumn 5, Issue 6, 2003, Pages 427-434

  Waeber, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; NITRENDIPINE; RESERPINE; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINA; CLINICAL TRIAL; DEMENTIA; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF CHOLESTEROL METABOLISM; DRUG EFFICACY; DRUG MEGADOSE; EUROPE; GERIATRIC PATIENT; HEALTH PROGRAM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERURICEMIA; HYPOKALEMIA; LOW DRUG DOSE; MULTIINFARCT DEMENTIA; REVIEW; STROKE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; AGED; CONTROLLED CLINICAL TRIAL; HYPERTENSION; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS;

EID: 1542780836     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-003-0103-3     Document Type: Review

References (43)

1. Kannel WB: Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999, 138:205-210.
2. He J, Whelton PK: Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999, 138:211-219.
3. Shrivastava S, Kochar MS: The need to lower systolic blood pressure. Current Hypertens Rep 2000, 2:433-440.
4. Staessen JA, Gasowski J, Wang JG, et al.: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355:865-872.
5. Franklin SS, Khan SA, Wong ND, et al.: Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999, 100:354-360.
6. Benetos A, Zureik M, Morcet J, et al.: A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000, 35:673-680.
7. Joffres MR, Hamer P, MacLean DR, et al.: Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001, 14:1099-1105.
8. Swales JD: Current status of hypertensive disease treatment: results from the Evaluation and Interventions for Systolic Blood Pressure Elevation: Regional and Global (EISBERG) Project. J Hypertens 1999, 17:S15-S19.
9. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264.
10. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757-764.
11. Liu L, Wang JG, Gong L, et al.: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998, 16:1823-1829.
12. Kjeldsen SE, Dahlof B, Devereux RB, et al.: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002, 288:1491-1498.
13. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999, 17:151-183.
14. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413-2446.
15. Waeber B: Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Press 2001, 10:62-73.
16. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
17. Perry HM Jr, Davis BR, Price TR, et al.: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000, 284:465-471.
18. Davis BR, Vogt T, Frost PH, et al.: Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. Stroke 1998, 29:1333-1340.
19. Franklin SS, Sutton-Tyrrell K, Belle SH, et al.: The importance of pulsatile components of hypertension in predicting carotid stenosis in older adults. J Hypertens 1997, 15:1143-1150.
20. Sutton-Tyrrell K, Wolfson SK Jr, Kuller LH: Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke 1994, 25:44-50.
21. Pannier BM, Guerin AP, Marchais SJ, London GM: Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001, 28:1074-1077.
22. Forette F, Boller F: Hypertension and the risk of dementia in the elderly. Am J Med 1991, 90:14-19.
23. Forette F, Seux ML, Staessen JA, et al.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
24. Abramson J, Berger A, Krumholz HM, Vaccarino V: Depression and risk of heart failure among older persons with cisolated systolic hypertension. Arch Intern Med 2001, 161:1725-1730.
25. Applegate WB, Pressel S, Wittes J, et al.: Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994, 154:2154-2160.
26. Fletcher AE, Bulpitt CJ, Thijs L, et al.: Quality of life on randomized treatment for isolated systolic hypertension: results from the Syst-Eur Trial. J Hypertens 2002, 20:2069-2079.
27. Ofili EO, Cohen JD, St Vrain JA, et al.: Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA 1998, 279:778-780.
28. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992, 5:95-110.
29. Kostis JB, Davis BR, Cutler J, et al.: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997, 278:212-216.
30. Pahor M, Short RI, Somes GW, et al.: Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 1998, 158:1340-1345.
31. Voyaki SM, Staessen JA, Thijs L, et al.: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001, 19:511-519.
32. Weinberger MH: Diuretics and their side effects. Dilemma in the treatment of hypertension. Hypertension 1988, 11:16-20.
33. Frishman WH: Beta-adrenergic receptor blockers. Adverse effects and drug interactions. Hypertension 1988, 11:21-29.
34. Savage PJ, Pressel SL, Curb JD, et al.: Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998, 158:741-751.
35. Siscovick DS, Raghunathan TE, Psaty BM, et al.: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994, 330:1852-1857.
36. Franse LV, Pahor M, Di Bari M, et al.: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000, 35:1025-1030.
37. Franse LV, Pahor M, Di Bari M, et al.: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000, 18:1149-1154.
38. Waeber B, Feihl F, Ruilope L: Diabetes and hypertension. Blood Pressure 2001, 10:311-321.
39. Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886-1892.
40. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677-684.
41. Staessen JA, Beilin L, Parati G, et al.: Task force IV: clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. Blood Press Monit 1999, 4:319-331.
42. Staessen JA, Thijs L, Fagard R, et al.: Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999, 282:539-546.
43. Verdecchia P, Clement D, Fagard R, et al.: Blood Pressure Monitoring. Task force III: Target-organ damage, morbidity and mortality. Blood Press Monit 1999, 4:303-317.